FCM
DYN icon

Frontier Capital Management’s Dyne Therapeutics DYN Stock Holding History

Frontier Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.9M Sell
821,849
-317,019
-28% -$5.47M 0.15% 193
2025
Q4 		$22.3M Buy
1,138,868
+227,949
+25% +$4.32M 0.24% 154
2025
Q3 		$11.5M Buy
910,919
+121,494
+15% +$1.39M 0.1% 235
2025
Q2 		$7.52M Buy
789,425
+499,822
+173% +$5.5M 0.07% 264
2025
Q1 		$3.03M Sell
289,603
-8,449
-3% -$121K 0.03% 272
2024
Q4 		$7.02M Buy
+298,052
New +$8.82M 0.07% 239

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Frontier Capital Management's DYN Position: Q1 2026 in Review

Frontier Capital Management reduced its Dyne Therapeutics (DYN) stake by 28% in Q1 2026, selling an estimated $5.47M and leaving 821,849 shares worth $14.9M. The position accounts for 0.15% of the portfolio, ranked #193.

Frontier Capital Management first reported a position in DYN in Q4 2024 and has held it in 6 quarters since. The position peaked at $22.3M in Q4 2025. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Frontier Capital Management held 821,849 shares of Dyne Therapeutics worth $14.9M as of Q1 2026.
  • Frontier Capital Management sold 317,019 Dyne Therapeutics shares in Q1 2026, an estimated $5.47M.
  • Dyne Therapeutics made up 0.15% of Frontier Capital Management's portfolio in Q1 2026, its #193 holding.
  • Frontier Capital Management first reported a position in Dyne Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Frontier Capital Management's Dyne Therapeutics position peaked at $22.3M in Q4 2025.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Frontier Capital Management's 13F filing for Q1 2026, filed 15 May 2026.